| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
LiquidSEQ(TM) with Reflex to Solid TumorSEQ(TM)
Test Code14343
CPT Codes
*ERRO (x0)
Preferred Specimen
10 mL Whole blood and Tissue [x2]; 1 block .
Collection Instructions:
__** This test is not available for Wyoming patient testing.
__** This test requires two Streck tubes AND a tumor
__specimen. Blood will be collected in office via
__QUEST-LIQUIDSEQ GEN KIT. Specimens may be shipped
__separately and at different times. Do not hold blood
__specimen due to short stability. Do not reject. A
__pathology report must accompany paraffin block or slides.
__Information required in this report includes: Physician
__identification, specimen identifiers (case and block
__number), specimen site and type, collection date,
__collection time, tissue processing used (routine or
__microwave), cold ishemic time, type of fixative, duration
__of fixation, pathologic diagnosis, and IHC score, if
__performed elsewhere. PLEASE NOTE: if Hospital Discharge
__Date is not populated, outpatient treatment is assumed. If
__unknown, please enter NG. PLEASE NOTE: This test can be
__ordered prior to the patients planned surgery. Please
__enter the planned Tissue collection date, and planned
__Specimen Location. For all other fields related to tissue
__procurement please enter NG Blood collection using a
__straight needle is preferred. Use kit only. All tubes must
__be filled completely. Gently invert tube at least 8 times
__immediately after draw. Note: If there are multiple blocks
__for the primary tumor, please send the block with the
__highest tumor content. Ship ambient or on ice pack in
__summer. For FFPE and slides a pathology report must be
__submitted with sample. Do not reject.
__
__Submit tissue in sterile biohazard plastic bag.
Collection Instructions:
__** This test is not available for Wyoming patient testing.
__** This test requires two Streck tubes AND a tumor
__specimen. Blood will be collected in office via
__QUEST-LIQUIDSEQ GEN KIT. Specimens may be shipped
__separately and at different times. Do not hold blood
__specimen due to short stability. Do not reject. A
__pathology report must accompany paraffin block or slides.
__Information required in this report includes: Physician
__identification, specimen identifiers (case and block
__number), specimen site and type, collection date,
__collection time, tissue processing used (routine or
__microwave), cold ishemic time, type of fixative, duration
__of fixation, pathologic diagnosis, and IHC score, if
__performed elsewhere. PLEASE NOTE: if Hospital Discharge
__Date is not populated, outpatient treatment is assumed. If
__unknown, please enter NG. PLEASE NOTE: This test can be
__ordered prior to the patients planned surgery. Please
__enter the planned Tissue collection date, and planned
__Specimen Location. For all other fields related to tissue
__procurement please enter NG Blood collection using a
__straight needle is preferred. Use kit only. All tubes must
__be filled completely. Gently invert tube at least 8 times
__immediately after draw. Note: If there are multiple blocks
__for the primary tumor, please send the block with the
__highest tumor content. Ship ambient or on ice pack in
__summer. For FFPE and slides a pathology report must be
__submitted with sample. Do not reject.
__
__Submit tissue in sterile biohazard plastic bag.
Minimum Volume
Tissue: 1 block
Whole blood: 10 mL [x2]
Whole blood: 10 mL [x2]
Unstained slides: 5 slides
Whole blood: 10 mL [x2]
Whole blood: 10 mL [x2]
Unstained slides: 5 slides
Other Acceptable Specimens
10 mL [x2] Whole blood and Unstained slides
10 slides
10 slides
Transport Container
Whole blood: Streck cell-free DNA blood collection tube [x2]
Tissue: Paraffin embedded tissue block
Whole blood: Streck cell-free DNA blood collection tube [x2]
Unstained slides: Slide holder
Tissue: Paraffin embedded tissue block
Whole blood: Streck cell-free DNA blood collection tube [x2]
Unstained slides: Slide holder
Transport Temperature
Whole blood: Room temperature acceptable; Refrigerated
_unacceptable; Frozen unacceptable
Tissue and Unstained slides: Room temperature preferred;
_Refrigerated acceptable; Frozen unacceptable
Whole blood: Room temperature preferred; Refrigerated
_unacceptable; Frozen unacceptable
_unacceptable; Frozen unacceptable
Tissue and Unstained slides: Room temperature preferred;
_Refrigerated acceptable; Frozen unacceptable
Whole blood: Room temperature preferred; Refrigerated
_unacceptable; Frozen unacceptable
Specimen Stability
Whole blood or Whole blood
__Room temperature: 7 Days
__Refrigerated: Unacceptable
__Frozen: Unacceptable
__-70 Degrees: Unacceptable
Tissue or Unstained slides
__Room temperature: Acceptable
__Refrigerated: Acceptable
__Frozen: Unacceptable
__-70 Degrees: Unacceptable
__Room temperature: 7 Days
__Refrigerated: Unacceptable
__Frozen: Unacceptable
__-70 Degrees: Unacceptable
Tissue or Unstained slides
__Room temperature: Acceptable
__Refrigerated: Acceptable
__Frozen: Unacceptable
__-70 Degrees: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Do not reject, send to laboratory, for testing assessment
Methodology
Next Generation Sequencing
Setup Schedule
A.M. Sets up 3 days a week.
Report Available
Reports in 8 to 11 days.
Clinical Significance
Plasma-based ctDNA tumor profiling with reflex to
tissue-based tumor profiling may be clinically useful in
specific circumstances such as when expedited biomarker
testing is needed to inform patient care or when tissue
adequacy or availability may be limited. The 523-gene
comprehensive genomic profiling panel is intended to help
oncologists deliver precision medicine by providing
personalized genomic analysis of a patient s tumor. This
comprehensive panel offers the opportunity for a broader
scope of genomic information compared to single gene tests
or smaller panels. For example, it may be useful for
patients with limited or ill-defined treatment options and
for those considering clinical trials. The test is designed
to detect single nucleotide variants (SNVs) and small
insertions/deletions, as well as whole-gene copy number
alterations and translocations in a select group of genes.
Microsatellite instability (MSI) and tumor mutation burden
(TMB) are also evaluated.
tissue-based tumor profiling may be clinically useful in
specific circumstances such as when expedited biomarker
testing is needed to inform patient care or when tissue
adequacy or availability may be limited. The 523-gene
comprehensive genomic profiling panel is intended to help
oncologists deliver precision medicine by providing
personalized genomic analysis of a patient s tumor. This
comprehensive panel offers the opportunity for a broader
scope of genomic information compared to single gene tests
or smaller panels. For example, it may be useful for
patients with limited or ill-defined treatment options and
for those considering clinical trials. The test is designed
to detect single nucleotide variants (SNVs) and small
insertions/deletions, as well as whole-gene copy number
alterations and translocations in a select group of genes.
Microsatellite instability (MSI) and tumor mutation burden
(TMB) are also evaluated.
